All publications

Export 168 results:
Author Title Type [ Year(Asc)]
2009
Geretti AM, Harrison LJ, Green H, Sabin CA, Hill T, Fearnhill E, Pillay D, Dunn DT.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Harrison LJ, Dunn DT, Green H, Copas A.  2009.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.
Hughes GJ, Fearnhill E, Dunn DT, Lycett S, Rambaut A, Leigh Brown A.  2009.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.
Hughes GJ, Leigh Brown A, Bollback J, Rambaut A, Fearnhill E, Dunn DT, UK Collaborative Group on HIV Drug Resistance.  2009.  Phylodynamic analysis of non-B HIV in the United Kingdom reveals substantial post-immigration transmission but longer intervals between transmissions than for subtype B. 16th Conference on Retroviruses and Opportunistic Infections, February 2009.
Price H., Dunn DT, Asboe D, Pozniak A, Gazzard B, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2009.  Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
2008
Geretti AM, Harrison LJ, Green H, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Effect of HIV-1 subtype on virological and immunological response to first-line HAART. 6th European HIV Drug Resistance Workshop, 26-28 March 2008.
Harrison LJ, Geretti AM, Green H, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Effect of HIV-1 subtype on virological and immunological response to first-line HAART. British HIV Association 14th Annual Conference, 23-25 April 2008.
Chakraborty R., Smith CJ, Dunn DT, Green H, Duong T., Doerholt K., Riordan A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.
Bansi L, Geretti AM, Dunn DT, Sabin CA, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips AN, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
Cozzi-Lepri A, Dunn DT, Pillay D, Sabin CA, Fearnhill E, Phillips AN, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Gifford RJM, de Oliveira T, Rambaut A, Pybus OG, Dunn DT, Vandamme A.M, Kellam P, Pillay D, UK HIV Drug Resistance Database.  2008.  Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Dunn DT, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin CA, Phillips AN.  2008.  Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.
Geretti AM, Phillips AN, Kaye S, Booth C, Garcia A, Mackie N, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. 17th International HIV Drug Resistance Workshop, 10-14 June 2008.
Hughes GJ, Leigh Brown A, Rambaut A, Lycett S, Lewis S, Fearnhill E, UK HIV Drug Resistance Database.  2008.  Recent phylodynamics of the HIV epidemic among MSM in the UK. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Chilton DN, Harrison LJ, Green H, Lattimore S, Delpech V, Pillay D.  2008.  Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.